Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma

Arata Tsutsumida, Satoshi Fukushima, Kenji Yokota, Shusuke Yoshikawa, Osamu Yamasaki, Atsushi Tanemura, Ryuhei Okuyama, Hisashi Uhara, Yusuke Muto, Azusa Miyashita, Masashi Akiyama, Tatsuya Kaji, Hiroshi Koga, Junji Kato, Teruaki Katayama, Eijun Itakura, Naoya Yamazaki, Yoshio Kiyohara

Research output: Contribution to journalArticle

Abstract

To describe the treatment patterns of nivolumab and ipilimumab in Japan, a retrospective observational study was conducted in melanoma patients who received nivolumab and ipilimumab sequentially. Patients who received nivolumab and ipilimumab in combination were excluded from this study. Efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) in terms of the overall response rate (ORR), progression-free survival (PFS), and disease control rate (DCR). Overall survival (OS) was also evaluated. Safety was assessed by the Common Terminology Criteria for Adverse Events (CTCAE). The treatment for all 68 patients enrolled involved switching from nivolumab to ipilimumab in 61 patients and switching from ipilimumab to nivolumab in seven patients. Switching occurred because of progressive disease in 55 patients and adverse events in eight patients. The median number of ipilimumab doses was three. Ipilimumab treatment achieved an ORR and DCR of 4.9% and 21.3%, respectively, and the median OS from start of ipilimumab was 7.0 months. During the study period, no new safety signals were noted. Independent factors which were indicative of poor prognosis for PFS were high neutrophil-to-lymphocyte ratio (NLR) and high C-reactive protein (CRP) levels before ipilimumab treatment. An evaluation over a washout period indicated that no significant relationship existed with efficacy or safety. For the sequential administration of nivolumab and ipilimumab in Japanese melanoma patients, switch from nivolumab to ipilimumab was common, and the major reason for switching was progressive disease. The major prognostic factors for ipilimumab PFS after nivolumab were NLR and CRP before ipilimumab treatment.

Original languageEnglish
Pages (from-to)947-955
Number of pages9
JournalJournal of Dermatology
Volume46
Issue number11
DOIs
Publication statusPublished - Nov 1 2019

Fingerprint

Melanoma
Disease-Free Survival
Safety
ipilimumab
nivolumab
C-Reactive Protein
Neutrophils
Lymphocytes
Therapeutics
Survival
Terminology
Observational Studies
Japan
Retrospective Studies

Keywords

  • ipilimumab
  • Japanese
  • melanoma
  • nivolumab
  • sequential therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Tsutsumida, A., Fukushima, S., Yokota, K., Yoshikawa, S., Yamasaki, O., Tanemura, A., ... Kiyohara, Y. (2019). Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. Journal of Dermatology, 46(11), 947-955. https://doi.org/10.1111/1346-8138.15073

Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. / Tsutsumida, Arata; Fukushima, Satoshi; Yokota, Kenji; Yoshikawa, Shusuke; Yamasaki, Osamu; Tanemura, Atsushi; Okuyama, Ryuhei; Uhara, Hisashi; Muto, Yusuke; Miyashita, Azusa; Akiyama, Masashi; Kaji, Tatsuya; Koga, Hiroshi; Kato, Junji; Katayama, Teruaki; Itakura, Eijun; Yamazaki, Naoya; Kiyohara, Yoshio.

In: Journal of Dermatology, Vol. 46, No. 11, 01.11.2019, p. 947-955.

Research output: Contribution to journalArticle

Tsutsumida, A, Fukushima, S, Yokota, K, Yoshikawa, S, Yamasaki, O, Tanemura, A, Okuyama, R, Uhara, H, Muto, Y, Miyashita, A, Akiyama, M, Kaji, T, Koga, H, Kato, J, Katayama, T, Itakura, E, Yamazaki, N & Kiyohara, Y 2019, 'Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma', Journal of Dermatology, vol. 46, no. 11, pp. 947-955. https://doi.org/10.1111/1346-8138.15073
Tsutsumida, Arata ; Fukushima, Satoshi ; Yokota, Kenji ; Yoshikawa, Shusuke ; Yamasaki, Osamu ; Tanemura, Atsushi ; Okuyama, Ryuhei ; Uhara, Hisashi ; Muto, Yusuke ; Miyashita, Azusa ; Akiyama, Masashi ; Kaji, Tatsuya ; Koga, Hiroshi ; Kato, Junji ; Katayama, Teruaki ; Itakura, Eijun ; Yamazaki, Naoya ; Kiyohara, Yoshio. / Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma. In: Journal of Dermatology. 2019 ; Vol. 46, No. 11. pp. 947-955.
@article{0717682fc4e34e5181a3f2b4faf1353f,
title = "Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma",
abstract = "To describe the treatment patterns of nivolumab and ipilimumab in Japan, a retrospective observational study was conducted in melanoma patients who received nivolumab and ipilimumab sequentially. Patients who received nivolumab and ipilimumab in combination were excluded from this study. Efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) in terms of the overall response rate (ORR), progression-free survival (PFS), and disease control rate (DCR). Overall survival (OS) was also evaluated. Safety was assessed by the Common Terminology Criteria for Adverse Events (CTCAE). The treatment for all 68 patients enrolled involved switching from nivolumab to ipilimumab in 61 patients and switching from ipilimumab to nivolumab in seven patients. Switching occurred because of progressive disease in 55 patients and adverse events in eight patients. The median number of ipilimumab doses was three. Ipilimumab treatment achieved an ORR and DCR of 4.9{\%} and 21.3{\%}, respectively, and the median OS from start of ipilimumab was 7.0 months. During the study period, no new safety signals were noted. Independent factors which were indicative of poor prognosis for PFS were high neutrophil-to-lymphocyte ratio (NLR) and high C-reactive protein (CRP) levels before ipilimumab treatment. An evaluation over a washout period indicated that no significant relationship existed with efficacy or safety. For the sequential administration of nivolumab and ipilimumab in Japanese melanoma patients, switch from nivolumab to ipilimumab was common, and the major reason for switching was progressive disease. The major prognostic factors for ipilimumab PFS after nivolumab were NLR and CRP before ipilimumab treatment.",
keywords = "ipilimumab, Japanese, melanoma, nivolumab, sequential therapy",
author = "Arata Tsutsumida and Satoshi Fukushima and Kenji Yokota and Shusuke Yoshikawa and Osamu Yamasaki and Atsushi Tanemura and Ryuhei Okuyama and Hisashi Uhara and Yusuke Muto and Azusa Miyashita and Masashi Akiyama and Tatsuya Kaji and Hiroshi Koga and Junji Kato and Teruaki Katayama and Eijun Itakura and Naoya Yamazaki and Yoshio Kiyohara",
year = "2019",
month = "11",
day = "1",
doi = "10.1111/1346-8138.15073",
language = "English",
volume = "46",
pages = "947--955",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma

AU - Tsutsumida, Arata

AU - Fukushima, Satoshi

AU - Yokota, Kenji

AU - Yoshikawa, Shusuke

AU - Yamasaki, Osamu

AU - Tanemura, Atsushi

AU - Okuyama, Ryuhei

AU - Uhara, Hisashi

AU - Muto, Yusuke

AU - Miyashita, Azusa

AU - Akiyama, Masashi

AU - Kaji, Tatsuya

AU - Koga, Hiroshi

AU - Kato, Junji

AU - Katayama, Teruaki

AU - Itakura, Eijun

AU - Yamazaki, Naoya

AU - Kiyohara, Yoshio

PY - 2019/11/1

Y1 - 2019/11/1

N2 - To describe the treatment patterns of nivolumab and ipilimumab in Japan, a retrospective observational study was conducted in melanoma patients who received nivolumab and ipilimumab sequentially. Patients who received nivolumab and ipilimumab in combination were excluded from this study. Efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) in terms of the overall response rate (ORR), progression-free survival (PFS), and disease control rate (DCR). Overall survival (OS) was also evaluated. Safety was assessed by the Common Terminology Criteria for Adverse Events (CTCAE). The treatment for all 68 patients enrolled involved switching from nivolumab to ipilimumab in 61 patients and switching from ipilimumab to nivolumab in seven patients. Switching occurred because of progressive disease in 55 patients and adverse events in eight patients. The median number of ipilimumab doses was three. Ipilimumab treatment achieved an ORR and DCR of 4.9% and 21.3%, respectively, and the median OS from start of ipilimumab was 7.0 months. During the study period, no new safety signals were noted. Independent factors which were indicative of poor prognosis for PFS were high neutrophil-to-lymphocyte ratio (NLR) and high C-reactive protein (CRP) levels before ipilimumab treatment. An evaluation over a washout period indicated that no significant relationship existed with efficacy or safety. For the sequential administration of nivolumab and ipilimumab in Japanese melanoma patients, switch from nivolumab to ipilimumab was common, and the major reason for switching was progressive disease. The major prognostic factors for ipilimumab PFS after nivolumab were NLR and CRP before ipilimumab treatment.

AB - To describe the treatment patterns of nivolumab and ipilimumab in Japan, a retrospective observational study was conducted in melanoma patients who received nivolumab and ipilimumab sequentially. Patients who received nivolumab and ipilimumab in combination were excluded from this study. Efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) in terms of the overall response rate (ORR), progression-free survival (PFS), and disease control rate (DCR). Overall survival (OS) was also evaluated. Safety was assessed by the Common Terminology Criteria for Adverse Events (CTCAE). The treatment for all 68 patients enrolled involved switching from nivolumab to ipilimumab in 61 patients and switching from ipilimumab to nivolumab in seven patients. Switching occurred because of progressive disease in 55 patients and adverse events in eight patients. The median number of ipilimumab doses was three. Ipilimumab treatment achieved an ORR and DCR of 4.9% and 21.3%, respectively, and the median OS from start of ipilimumab was 7.0 months. During the study period, no new safety signals were noted. Independent factors which were indicative of poor prognosis for PFS were high neutrophil-to-lymphocyte ratio (NLR) and high C-reactive protein (CRP) levels before ipilimumab treatment. An evaluation over a washout period indicated that no significant relationship existed with efficacy or safety. For the sequential administration of nivolumab and ipilimumab in Japanese melanoma patients, switch from nivolumab to ipilimumab was common, and the major reason for switching was progressive disease. The major prognostic factors for ipilimumab PFS after nivolumab were NLR and CRP before ipilimumab treatment.

KW - ipilimumab

KW - Japanese

KW - melanoma

KW - nivolumab

KW - sequential therapy

UR - http://www.scopus.com/inward/record.url?scp=85073936676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073936676&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.15073

DO - 10.1111/1346-8138.15073

M3 - Article

C2 - 31531895

AN - SCOPUS:85073936676

VL - 46

SP - 947

EP - 955

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 11

ER -